Kaposi sarcoma : Appraisal of therapeutic agents
β Scribed by Liron Pantanowitz
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 51 KB
- Volume
- 112
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Despite major advancements, the optimal treatment for Kaposi sarcoma has yet to be defined. Comparable standards employing existing therapies to satisfactorily manage all epidemiologic forms of Kaposi sarcoma, and the utilization of mechanismβbased therapeutic strategies with innovative surrogate endpoints to appraise their efficacy, are required.
π SIMILAR VOLUMES
## Background: Classical kaposi sarcoma (cks) is a rare indolent neoplasm that is particularly prevalent among jews of ashkenazi and mediterranean origin. data regarding prognostic factors for cks are scarce. the aim of the current retrospective analysis was to better define prognostic subgroups am
A retrospective study of 53 cases with a tistological diagnosis of Kaposi's sarcoma (KS) reported to The Cancer Registry of Norway during a five year period is presented. Four cases were excluded from the material because further information contradicted the diagnosis of KS. Of the remaining 49 case
An association between Kaposi's sarcoma (KS) and malignant lymphoma has been suspected for many years. Both cancers belong to the group of malignancies associated with immune suppression and have been known to occur in the same individual. Accordingly, a common etiology has been suspected. Through l